Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 1;44(4):E1-E10.
doi: 10.1503/jpn.180136.

Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study

Affiliations

Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study

Anna E. Leeuwis et al. J Psychiatry Neurosci. .

Abstract

Background: We investigated the association between white matter hyperintensity location and depressive symptoms in a memoryclinic population using lesion–symptom mapping.

Methods: We included 680 patients with vascular brain injury from the TRACE-VCI cohort (mean age ± standard deviation: 67 ± 8 years; 52% female): 168 patients with subjective cognitive decline, 164 with mild cognitive impairment and 348 with dementia. We assessed depressive symptoms using the Geriatric Depression Scale. We applied assumptionfree voxel-based lesion–symptom mapping, adjusted for age, sex, total white matter hyperintensity volume and multiple testing. Next, we applied exploratory region-of-interest linear regression analyses of major white matter tracts, with additional adjustment for diagnosis.

Results: Voxel-based lesion–symptom mapping identified voxel clusters related to the Geriatric Depression Scale in the left corticospinal tract. Region-of-interest analyses showed no relation between white matter hyperintensity volume and the Geriatric Depression Scale, but revealed an interaction with diagnosis in the forceps minor, where larger regional white matter hyperintensity volume was associated with more depressive symptoms in subjective cognitive decline (β = 0.26, p < 0.05), but not in mild cognitive impairment or dementia.

Limitations: We observed a lack of convergence of findings between voxel-based lesion–symptom mapping and region-of-interest analyses, which may have been due to small effect sizes and limited lesion coverage despite the large sample size. This warrants replication of our findings and further investigation in other cohorts.

Conclusion: This lesion–symptom mapping study in depressive symptoms indicates the corticospinal tract and forceps minor as strategic tracts in which white matter hyperintensity is associated with depressive symptoms in memory-clinic patients with vascular brain injury. The impact of white matter hyperintensity on depressive symptoms is modest, but it appears to depend on the location of white matter hyperintensity and disease severity.

PubMed Disclaimer

Conflict of interest statement

N. Prins serves on the advisory board of Boehringer Ingelheim and Probiodrug, and on Abbvie’s DSMB M15-566 trial; has provided consultancy services for Sanofi, Takeda and Kyowa Kirin Pharmaceutical Development; receives research support from Alzheimer Nederland (project number WE.03-2012-02); and is the CEO and co-owner of Brain Research Centre, Amsterdam, the Netherlands. P. Scheltens has acquired grant support (for the institution) from GE Healthcare and Piramal; and in the past 2 years he has received consultancy/speaker fees (paid to the institution) from Medavante, Novartis, Probiodrug, Biogen, Roche, Toyama and EIP Pharma. F. Barkhof serves as a consultant for Biogen-Idec, Janssen Alzheimer Immunotherapy, Bayer-Schering, Merck-Serono, Roche, Novartis, Genzyme and Sanofi-aventis; has received sponsoring from EU-H2020, NWO, SMSR, TEVA, Novartis, Toshiba and Imi; and serves on the editorial boards of Radiology, Brain, Neuroradiology, MSJ and Neurology. Research programs of W.M. van der Flier have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, Cardiovasculair Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis fonds, Pasman Stichting, Boehringer Ingelheim, Piramal Imaging, Roche BV, Janssen Stellar, Biogen and Combinostics; all funding is paid to her institution. G. Biessels has been funded by the Dutch Heart Association, ZonMW, the Netherlands Organisation for Health Research and Development and European Union Horizon 2020. No other competing interests declared.

Figures

Fig. 1
Fig. 1
Flow chart for patient selection. GDS = Geriatric Depression Scale.
Fig. 2
Fig. 2
Voxel-based lesion–symptom mapping: lesion prevalence map and results. (A) Voxel-wise lesion prevalence of white matter hyperintensities in the study population, projected on the Montreal Neurological Institute 152 T1 template. A minimum threshold of 14 participants with damage in a given voxel was applied; z-coordinates: −5, 5, 15, 25, 35. Voxel-based lesion–symptom mapping results for the Geriatric Depression Scale score, shown in (B) axial, (C) sagittal and (D) coronal planes. Significant voxels after correction for multiple comparisons, age, sex and normalized total white matter hyperintensity volume are shown in red (settings: Brunner–Munzel test; FDR q < 0.05). Significant voxels were located in the corticospinal tract. Regions of interest were derived from the Johns Hopkins University diffusion tensor imaging atlas with a probability threshold of 10%. The corticospinal tract derived from the Johns Hopkins University atlas is shown in blue; the voxels included in the voxel-based lesion–symptom mapping analysis (i.e., damaged in ≥ 14 participants) are shown in yellow. Coordinates: sagittal: x = −25; coronal: y = −32; axial: z = 33, 38. CST = corticospinal tract; FDR = false detection rate; WMH = white matter hyperintensity.

References

    1. World health statistics 2007. Geneva: World Health Organization; 2007. Available: www.who.int/whosis/whostat/2007/en/
    1. van Agtmaal MJM, Houben AJHM, Pouwer F, et al. Association of microvascular dysfunction with late-life depression. JAMA Psychiatry. 2017;74:729. - PMC - PubMed
    1. Anor CJ, O’Connor S, Saund A, et al. Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia. Neurodegener Dis. 2017;17:127–34. - PubMed
    1. Wang L, Leonards CO, Sterzer P, et al. White matter lesions and depression: a systematic review and meta-analysis. J Psychiatr Res. 2014;56:56–64. - PubMed
    1. Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular depression” hypothesis. Arch Gen Psychiatry. 1997;54:915–22. - PubMed

Publication types

MeSH terms

LinkOut - more resources